Harvard has decided not to seek to renew NIH support for their New England National Primate Research Center, established by Congress in 1962. The Center has operated with a so-called “base grant” from the National Institutes of Health underpinning the not-inconsiderable costs of housing thousands of nonhuman primates and the usual grab bag of investigators’ independent sources of funding. The NENPRC site lists an impressive series of accomplishments.
First unambiguous evidence that AIDS is caused by a virus.
Discovery of Simian Immunodeficiency Virus (SIV) and development of first animal model of AIDS.
Original demonstration that vaccine protection against AIDS is theoretically possible.
Discovery that a gene product of the AIDS virus activates lymphocytes necessary for disease progression.
Identification of therapeutic genes that can prevent infection of cells by the AIDS virus.
First demonstration that protective genes introduced into blood stem cells can block HIV or SIV infection.
Discovery of primitive blood stem cells lacking CD34 and their implications for bone marrow transplantation
Isolation of type-D retroviruses as major causes of illness and death in macaques.
Discovery of the oncogenic herpesvirus, Herpesvirus saimiri.
Discovery of a nonhuman primate virus closely related to the human Kaposi’s sarcoma-associated herpesvirus.
First nonhuman primate models of colon cancer and inflammatory bowel disease.
Evidence leading to the use of hydroxyurea to treat sickle cell anemia.
Discovery of stunned myocardium and its role in myocardial ischemia.
Discovery of cellular organization and critical period for development of the visual cortex.
First unambiguous evidence for the addictive properties of nicotine.
Identification of major risk factors in self-injurious behavior.
First animal model for progressive neurodegeneration in Parkinson’s disease.
Development of improved brain imaging techniques for early diagnosis of Parkinson’s disease.
Development of novel cellular and pharmacological strategies for treatment of Parkinson’s disease.
First survey of distribution of cocaine binding sites in primate brain.
Identification of the dopamine transporter as a principal target for cocaine in the brain.
First nonhuman primate model of drug relapse.
Development of novel drug classes to treat cocaine addiction and other brain dopamine disorders.
Most of the news reporting has focused on a series of lapses in the care of nonhuman primate subjects, leading to several deaths. I cannot comment on the degree to which this situation reflected lapses in the system, but clearly Harvard was undergoing major corrective measures. The news accounts describe situations which seem to me to be procedural lapses that have relatively straightforward fixes. Nothing appears to be systematically unfixable…again, going by the news accounts.
The Harvard Medical School press release is slightly more instructive, however.
The decision to conclude NEPRC operations follows a two-year period during which the Center leadership successfully addressed operating issues with input from the NIH and other governing agencies. The process resulted in new procedures that have significantly strengthened the Center’s day-to-day activities and that can serve as a model for other institutions throughout the country. Many of those changes carried additional costs, and HMS will continue to make investments in the Center to ensure ongoing compliance with all federal regulations.
Right? So the problems were fixable and they’d been investing in fixing them for two years. “Additional costs”, eh? Well, no biggie if the investment is good.
But what has happened in the past several months, hmm? The sequester. The Continuing Resolution for FY2013. Obama’s budget request for FY2014. None of this is good news. If you look at the NENPRC as effectively a small, soft-money research institute funded in large extent by federal grants (and let’s face it, partnering with for-profits isn’t going that well for academia right now either) then its prospects are pretty dim. Look at the situation through the lens of Return on Investment and everything becomes clear.
As they weighed whether to renew the base grant from the NIH, HMS leaders made a strategic decision based on a review of the long-term academic benefits and the financial cost of continuing to operate the NEPRC.
“Deciding how to best assign our limited resources is not unique to HMS,” said Jeffrey S. Flier, Dean of the Faculty of Medicine of Harvard University,
also…
Driving the decision was the fact that the external funding environment for scientific research has become increasingly challenging over the past decade. Recent funding pressures have added uncertainty to this already-challenging fiscal context. As Harvard Medical School leadership evaluated the long-term need to use its resources in the most effective manner across all of its missions, they came to the conclusion that winding down the operations of the NEPRC was more beneficial to the School than investing further resources in maintaining and renewing the NEPRC grant.
So yeah, this looks from the outside like a small, specialized research institute closing down due to the NIH funding situation to me.
Maybe I have NIH grant myopia but this is the way it looks.
I am reviewing some of the claims made about their listed accomplishments and going back to the original papers, where I can deduce them. In a few areas that I am familiar with….man. Straight up. These are valid claims, even if we recognize that no science breakthrough arrives entirely by itself. And more importantly, particularly when it came to the early days of AIDS, I am having trouble imagining how progress could have been made so rapidly without one of the National Primate Research Centers. They really do seem to serve a unique function in the NIH / US Federal extramural research enterprise and it would be a shame if this was merely the lead indicator in shuttering the whole program.
__
Disclaimer: I have professional acquaintances that work at NENPRC. I am disturbed that they are losing their jobs and I do hope that they get snapped up by some other University.
DrugMonkey 